Abbott Laboratories v. Rhealyn Alexander

698 F.3d 568
CourtCourt of Appeals for the Seventh Circuit
DecidedOctober 16, 2012
Docket12-8020, 12-8021, 12-8022, 12-8023, 12-8024, 12-8025, 12-8026, 12-8027
StatusPublished
Cited by23 cases

This text of 698 F.3d 568 (Abbott Laboratories v. Rhealyn Alexander) is published on Counsel Stack Legal Research, covering Court of Appeals for the Seventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Abbott Laboratories v. Rhealyn Alexander, 698 F.3d 568 (7th Cir. 2012).

Opinion

TINDER, Circuit Judge.

The parties petition us to resolve two conflicting district court decisions and decide whether a motion to consolidate and transfer related state court cases to one circuit court through trial constitutes a proposal to try the cases jointly, thus triggering the “mass action” provision of the Class Action Fairness Act (“CAFA”), 28 U.S.C. § 1332(d)(ll)(B)(i). We grant the petitions for review in order to resolve the differing approaches by the two district courts, and because the petitions present a novel issue, see Koral v. Boeing Co., 628 F.3d 945, 946 (7th Cir.2011), where a decision will be helpful to future litigants. We hold that plaintiffs’ motion to consolidate did propose a joint trial, and thus removal was proper.

Between August 2010 and November 2011 several hundred plaintiffs filed ten lawsuits in Illinois state court against Abbott Laboratories for personal injuries they allege were caused by Depakote, a prescription medication Abbott developed and markets. 1 Plaintiffs filed their lawsuits in St. Clair County, Madison County, and Cook County. In December 2011 plaintiffs moved the Supreme Court of Illinois to consolidate and transfer their cases *571 to St. Clair County, pursuant to Illinois Supreme Court Rule 384. Abbott opposed the motion, and as of this date, the Supreme Court has not ruled. Rule 384(a) says:

Motion to Consolidate — Transfer. When civil actions involving one or more common questions of fact or law are pending in different judicial circuits, and the supreme court determines that consolidation would serve the convenience of the parties and witnesses and would promote the just and efficient conduct of such actions, the supreme court may, on its own motion or on the motion of any party filed with the supreme court, transfer all such actions to one judicial circuit for consolidated pretrial, trial, or post-trial proceedings.

Plaintiffs asked for consolidation of their lawsuits in St. Clair County because the cases “present common questions of fact concerning Abbott’s development, testing, manufacturing, and marketing of Depakote, as well as common questions of law regarding Abbott’s liability for same” and “Consolidation will eliminate duplicative discovery and pretrial litigation, prevent inconsistent pretrial and trial rulings, and thereby promote judicial efficiency.” In the memorandum in support of their motion, plaintiffs said they were requesting consolidation of the cases “through trial” and “not solely for pretrial proceedings.” 2

Abbott removed each of the cases to federal court, asserting that the motion to consolidate brought the cases under CAFA’s “mass action” provision, which allows the removal of any case where 100 or more people propose to try their claims jointly. The cases filed in St. Clair County and Madison County were removed to the Southern District of Illinois and the cases filed in Cook County were removed to the Northern District of Illinois; plaintiffs moved to remand in both courts.

Judge Murphy in the Southern District ruled on plaintiffs’ motions to remand first, granting the motions on April 17, 2012. He held that Abbott’s arguments were foreclosed by our decision in Anderson v. Bayer, 610 F.3d 390 (7th Cir.2010), and concluded that the language in the motion to consolidate did not propose a joint trial. He said, “it appears that Plaintiffs contemplate consolidated discovery and pretrial proceedings, but not a joint trial of the hundreds of claims asserted in the ten subject cases. This is consistent with the Court’s experience, in which so-called ‘mass tort’ cases are never tried in their entirety, and instead ‘bellwether’ claims selected by the parties are tried individually in order to answer difficult issues of causation or liability common to all the claims and/or to value the remaining claims in the case for purposes of settlement.” Judge Darrah disagreed, and on May 9, 2012, denied plaintiffs’ motion to remand. He said the motion to consolidate “clearly intends to move the Illinois Supreme Court to consolidate the 10 complaints for all purposes, including (as they specifically indicate) for purposes of conducting a trial.” Abbott petitioned us to review Judge Murphy’s decision, and plaintiffs petitioned for review of Judge Darrah’s decision. The parties now seem to agree that interlocutory review is warranted but dispute whether plaintiffs’ cases constitute a mass action.

Section 1332(d)(ll)(B)(i) defines a mass action as “any civil action ... in which monetary relief claims of 100 or more persons are proposed to be tried jointly on the *572 ground that the plaintiffs’ claims involve common questions of law or fact.” Under CAFA, such mass actions are removable to federal court, so long as CAFA’s other jurisdictional requirements are met. Id. § 1332(d)(ll)(A). The parties do not dispute that the other requirements are met in each of the cases.

Plaintiffs argue that they did not propose a joint trial because their motion to consolidate did not address how the trials of the various claims in the cases would be conducted, other than proposing that they all take place in the Circuit Court of St. Clair County. Their motion and memorandum do not propose that one or more of the cases be tried jointly or that all parties would be bound by the findings of one trial. Rather, plaintiffs contend, their motion simply requests that the cases be coordinated through trial. If the motion is granted the transferee trial court would decide how to administer the cases, including how any trial would be conducted. In plaintiffs’ view, for the mass action provision to apply they would need to take the further step of requesting a joint trial or an exemplar trial that would affect the remaining cases.

We have addressed CAFA’s mass action provision several times, but never in the context of a motion to consolidate. Judge Murphy concluded that Abbott’s position was foreclosed by our decision in Anderson, 610 F.3d 390. There, plaintiffs filed five separate but mostly identical complaints in state court. Bayer argued that plaintiffs were attempting to circumvent CAFA’s mass action provision by artificially splitting their claims into five cases. We looked at CAFA’s statutory language and held that the complaints did not constitute a mass action because plaintiffs never proposed to try their claims jointly. Id. at 393; see Tanoh v. Dow Chem. Co., 561 F.3d 945, 953 (9th Cir.2009) (reaching similar conclusion). As long as plaintiffs had not proposed a joint trial, “[t]he mass action provision gives plaintiffs the choice to file separate actions that do not qualify for CAFA jurisdiction.” Anderson, 610 F.3d at 393. Under the reasoning of Anderson,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Brian Adams v. 3M Company
65 F.4th 802 (Sixth Circuit, 2023)
53 Stanhope LLC
S.D. New York, 2021
Warren Lester v. Exxon Mobil Corporation, e
879 F.3d 582 (Fifth Circuit, 2018)
Jerry Dunson v. Cordis Corporation
854 F.3d 551 (Ninth Circuit, 2017)
Melissa Ramirez v. Vintage Pharmaceuticals LLC
852 F.3d 324 (Third Circuit, 2017)
Justine Briggs v. Merck Sharp & Dohme
796 F.3d 1038 (Ninth Circuit, 2015)
Margalit Corber v. Xanodyne Pharmaceuticals, Inc.
771 F.3d 1218 (Ninth Circuit, 2014)
Time Insurance v. Astrazeneca AB
52 F. Supp. 3d 705 (E.D. Pennsylvania, 2014)
Teague v. Johnson & Johnson
749 F.3d 879 (Tenth Circuit, 2014)
Dawn Atwell v. Boston Scientific Corporation
740 F.3d 1160 (Eighth Circuit, 2013)
Judith Romo v. Teva Pharmaceuticals USA, Inc.
731 F.3d 918 (Ninth Circuit, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
698 F.3d 568, Counsel Stack Legal Research, https://law.counselstack.com/opinion/abbott-laboratories-v-rhealyn-alexander-ca7-2012.